chevron_leftBack
As of 24 April 2025, FamiCord AG has a market cap of $80.54M USD, ranking #21971 globally and #282 in Germany. It ranks #2190 in the Healthcare sector, and #194 in the Medical Care Facilities industry.
Key Stats
Market Cap
$80.54MUSD
70.77M EUR
Enterprise Value
$80.76MUSD
70.97M EUR
Revenue (TTM)
$91.77MUSD
80.64M EUR
EBITDA (TTM)
$6.18MUSD
5.43M EUR
Net Income (TTM)
$2.94MUSD
2.58M EUR
EBITDA Margin
6.7%
Profit Margin
3.2%
PE Ratio
28.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Jakub Baran
open_in_new
Employees
745
Founded
1997
Website
famicord.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -1.5% | -2.4% | -1.9% | -9.8% | -15% |
Upcoming Earnings
Earnings Date
Wed, Apr 30
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
V3V
ISIN: DE000A0BL849
Shares Out.:
Shares Outstanding:
17.432M1
Shares Float:
5.56M2
|
4.06 EUR | |
|
0NLV
FamiCord AG
ISIN: DE000A0BL849
|
4.08 EUR | |
|
V3V
ISIN: DE000A0BL849
|
4.06 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About FamiCord AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.
